The use of topical Healon tears in the management of refractory dry-eye syndrome.
We evaluated 28 patients with dry-eye syndrome in the setting of either primary or secondary Sjogren's syndrome, with topical Healon tears. In 26 of the 28 patients, we noted both subjective and objective improvement characterized by decreased itching, burning and foreign body sensation, decreased mucus stranding and Rose-Bengal staining of the cornea and conjunctiva, and increased corneal luster and tear break-up time.
D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000818:Animals; D002645:Chickens; D005260:Female; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D007766:Lacrimal Apparatus Diseases / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012859:Sjogren's Syndrome / Q000188:drug therapy*; D013666:Tears / Q000187:drug effects / Q000378:metabolism*
D006820:Hyaluronic Acid